Jenburkt Pharmaceuticals Ltd Share Price Today - Jenburkt Pharmaceuticals Ltd Stock Price Live NSE/BSE

Jenburkt Pharmaceuticals Ltd

NSE: BSE: 524731

₹1004

(0.93%)

Tue, 10 Mar 2026, 03:54 pm

MTF 5xInvest in Jenburkt Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap4.43B

PE Ratio13.67

Dividend1.79

Health Technology

Pharmaceuticals: Major

24.5K

Jenburkt Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
440.58
Net Profit
32.06
P/B
2.60
Sector P/E
40.49
P/E
13.93
EV/EBITDA
9.04
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.89
ROCE (Industry)
16.43
RONW (Industry)
14.36
ROE
20.25
ROCE
27.18
Debt/Equity
0.01
EPS (TTM)
73.47
Dividend Yield
1.80
Book Value
414.39
Interest Cover
98.62

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.7x coverage).
Jenburkt Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Jenburkt Pharmaceuticals's dividend is above the markets top 25% of dividend payers in India (3.08%).
Jenburkt Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
High level of physical assets or inventory.
Ashish's remuneration is higher than average for companies of similar size in India.
Jenburkt Pharmaceuticals is not covered by any analysts.
Jenburkt Pharmaceuticals has significant price volatility in the past 3 months.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	46.65	46.66	46.67	46.68	46.69
FII	0	0	0	0	0
DII	0.12	0.12	0.12	0.12	0.12
Public	53.24	53.22	53.22	53.20	53.20
Government	0	0	0	0	0

Technical Analysis

RSI

46.20

MACD

-17.48

50 DMA

1059.56

200 DMA

1155.97

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1315.33	1175.33	1089.67	1035.33	949.67	895.33	755.33
Fibonacci	1175.33	1121.85	1088.81	1035.33	981.85	948.81	895.33
Camarilla	1042.50	1029.67	1016.83	1035.33	991.17	978.33	965.50

Pivots Level: Classic

+280

1315.33

+140

1175.33

+54.33

1089.67

1035.33

Pivot Point

LTP: 1018.85

-85.67

949.67

-140

895.33

-280

755.33

Moving Average

SMAEMA

Period

Value

10-EMA
1008.66
20-EMA
1021.11
30-EMA
1032.96
50-EMA
1052.32
100-EMA
1083.96
200-EMA
1104.88

Announcement Date	Purpose	Action	Ex Date
03 Feb 2026	board-meetings	Quarterly Results
11 Jun 2025	dividend	Final Dividend - Rs. - 18	11 Jul 2025
20 May 2025	agm
20 May 2025	dividend	₹18.00 Dividend /Share	11 Jul 2025
28 May 2024	dividend	₹15.30 Dividend /Share	24 Jul 2024
28 May 2024	agm
23 May 2023	dividend	₹14.40 Dividend /Share	20 Jul 2023
23 May 2023	agm
01 Dec 2022	buyback
27 May 2022	agm

Jenburkt Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Cipla Ltd

Jenburkt Pharmaceuticals Ltd About

Jenburkt Pharmaceuticals is in the business of manufacturing, producing, developing and marketing a wide range of branded Pharmaceuticals and health care products. (Source : 202503 Annual Report Page No: 57)

Industry

Pharmaceuticals - Indian - Formulations

Founded

1985

Headquarters

CEO

Ashish U Bhuta

Employees

Contact

Website

http://www.jenburkt.com

investor@jenburkt.com

Phone

91-22-66943121/67603603

Location

Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W), Mumbai, Maharashtra, 400058

Year	History
2012	Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs. 3.50 (35%) per equity share of Rs. 10/- each.
2013	Shri. Ashish U. Bhuta has been appointed as the Chairman and Managing Director of the Company
2014	The Company has recommended a Dividend of Rs. 5.10 (51%) per equity share of Rs. 10/- each. Ms. Devangi Sanjeev Shah has been appointed as Woman Director
2020	Jenburkt launched Favipiravir (Favivent) to fight COVID-19
2022	The Company Launched a new product ZIXA STRONG on e-commerce websites.

Client Name	Order Side	QTY	Avg Price	Date
JENBURKT PHARMACEUTICALS LTD	Buy	47037	649.97	06 Jan 2023
ARIES STOCKTRADES PVT LTD A/C-PMS	Sell	26000	410.39	25 Aug 2020
TRUPTI KETAN KARANI	Sell	26000	540.5	08 Feb 2018
KETAN JAYANTILAL KARANI (HUF)	Buy	26000	540.5	08 Feb 2018
RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED	Buy	23887	465	24 Oct 2017
GIRIK WEALTH ADVISORS PRIVATE LIMITED-DEEP VALUE PMS	Sell	30794	433.26	05 Sept 2017
Aries Stocktrades Pvt Ltd A/c-PMS	Buy	23591	566.67	04 Nov 2016
KAUSHIK PARASKUMAR DAGA	Buy	30000	347.12	30 Jan 2015
DINERO WEALTH ADVISORS PRIVATE LIMITED	Sell	30000	347.03	30 Jan 2015
DINERO WEALTH ADVISORS PRIVATE LIMITED	Buy	28646	187.95	30 Jul 2014

Jenburkt Pharmaceuticals Ltd News

Jenburkt Pharmaceuticals Q3FY26 Results

Jenburkt Pharmaceuticals reported Q3FY26 revenue of Rs 4302.39 lacs and net profit of Rs 593.14 lacs. Nine-month revenue reached Rs 12410.83 lacs with profit of Rs 2388.66 lacs.

03 Feb 2026

co actions results

Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026

Jenburkt Pharmaceuticals Limited announced its quarterly results for the quarter ended September 30, 2025. Revenue from operations increased to Rs 4,555.7 lacs compared to Rs 4,121.5 lacs in the same quarter last year, representing a 10.5% growth. Profit after tax rose to Rs 1,133.2 lacs from Rs 1,018.2 lacs year-over-year. For the half-year period, total revenue reached Rs 8,108.4 lacs versus Rs 7,375.16 lacs in the previous year. The company operates exclusively in the pharmaceuticals business segment. The Board meeting was held on October 28, 2025, where the Audit Committee recommended and the Board approved these unaudited financial results.

28 Oct 2025

earnings

Jenburkt Pharmaceuticals Reports 5.1% Growth in Profit After Tax for Quarter Ended June 30, 2025

Jenburkt Pharmaceuticals Limited reported profit after tax of Rs. 779.18 lacs for the quarter ended June 30, 2025, compared to Rs. 741.60 lacs in the same quarter previous year. Revenue from operations increased to Rs. 3,552.68 lacs from Rs. 3,253.57 lacs year-over-year. Total comprehensive income reached Rs. 916.61 lacs versus Rs. 896.68 lacs in the corresponding quarter. Earnings per share stood at Rs. 17.66 compared to Rs. 16.80 in the same period last year. The company operates exclusively in the pharmaceuticals business segment. The board meeting was held on August 12, 2025, where the Audit Committee reviewed and the Board approved these standalone unaudited financial results.

12 Aug 2025

earnings

Jenburkt Pharmaceuticals Reports Q4 Results and Recommends Dividend

Jenburkt Pharmaceuticals has announced its Q4 financial results and recommended a dividend. The company's Q4 revenue increased to 410.5 million rupees from 388 million rupees year-over-year. EBITDA rose to 108.6 million rupees from 98.5 million rupees, with the EBITDA margin improving to 26.45% from 24.37%. Net profit for Q4 grew to 85.4 million rupees from 79 million rupees in the previous year. The company has recommended a dividend of 18 rupees per equity share.

20 May 2025

result

Jenburkt Pharmaceuticals: Q3 Profit Rises 20.56% YoY Despite Quarterly Decline

Jenburkt Pharmaceuticals reported Q3 FY25 results with profit at ₹6.51 crore, up 20.56% YoY, and revenue at ₹36.89 crore, up 3.45% YoY. However, compared to Q2, revenue declined 10.5% and profit fell 32.19%. Operating income increased 22.37% YoY but decreased 25.49% QoQ. EPS rose to ₹14.75, up 20.41% YoY.

29 Jan 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800